Published: 2021-11-25

Efficacy and safety of ferric carboxymaltose in Indian pregnant women with iron deficiency anemia

Vidya Bhat, Brunda Kiran, Girish Deshmukh, Ketan Kulkarni, Ajinkya Rodge


Background: Iron deficiency anemia (IDA) is a significant problem worldwide particularly in women. The aim of the study was to evaluate the effectiveness of intravenous ferric carboxymaltose (FCM) in in Indian pregnant women with anemia.

Method: This was a single centre, prospective, observational, open label, clinical study at real life scenario with 4 weeks follow up. Fifty pregnant women with IDA and visiting to the Radhakrishna multispecialty hospital, Bangalore, for antenatal care were enrolled for the study. IV FCM was given as per the standard protocol. Change in the laboratory parameters such as hemoglobin, mean corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), packed cell volume (PCV) level at baseline and after 4 weeks of completion of parenteral iron therapy was recorded and fatigue score was assessed. The pregnant women were monitored for the adverse events. 

Results: All pregnant women received a single IV infusion of FCM 1000 mg. A significant increase in the hemoglobin of 2.37±0.51 g/dl (p<0.001) was noted at 4 weeks, MCV rise of 19.89±21.94 (p<0.001) was noted at 4 weeks, MCHC rise was of 2.56±5.65 and PCV rise was of 4.45±2.67 (p<0.011) at over 4 weeks. Significant improvement in fatigue score was observed at 4 weeks after single FCM infusion. No adverse effects were observed in any pregnant woman throughout the duration of the study.

Conclusions: This real-life observational study highlights IV FCM is effective in management of IDA in pregnant women and well tolerated. 

Trial registration number: CTRI/2021/02/030874



IDA, FCM, Hemoglobin, MCV, MCHC, PCV

Full Text:



Breymann C. Iron deficiency anemia in pregnancy. Semin Hematol. 2015;52(4):339-47.

Haider BA, Olofin I, Wang M, Spiegelman D, Ezzati M, Fawzi WW et al. Anaemia, prenatal iron use, and risk of adverse pregnancy outcomes: systematic review and meta-analysis. BMJ. 2013;346:f3443.

National Family Health Survey (NFHS-5), 2019-20. Key Indicators-22 STATES/UTs FROM PHASE I. Available at: NFHS%20State%20Factsheet%20Compendium_Phase-I.pdf. Accessed on 12 April, 2020.

Rahman MM, Abe SK, Rahman MS. Maternal anemia and risk of adverse birth and health outcomes in low-and middle-income countries: systematic review and meta-analysis. Am J Clin Nutr. 2016;103(2):495-504.

Bharat AM. Operational Guidelines by Ministry of Health and Family Welfare Government of India. 2018.

Tandon R, Jain A, Malhotra P. Management of Iron Deficiency Anemia in Pregnancy in India. Indian J Hematol Blood Transfus. 2018;34(2):204-15.

Jose A, Mahey R, Sharma JB, Bhatla N, Saxena R, Kalaivani M et al. Comparison of ferric Carboxymaltose and iron sucrose complex for treatment of iron deficiency anemia in pregnancy- randomised controlled trial. BMC Pregnancy Childbirth. 2019;19(1):54.

Kruske SG, Ruben AR, Brewster DR. An iron treatment trial in an aboriginal community: improving non-adherence. J Paediatr Child Health. 1999;35:153-8.

Longo SA, Moore RC, Canzoneri BJ, Robichaux A. Gastrointestinal Conditions during Pregnancy. Clin Colon Rectal Surg. 2010;23(2):80-9.

Kriplani A, Mahey R, Dash BB, Kulshreshta V, Agarwal N, Bhatla N. Intravenous iron sucrose therapy for moderate to severe anaemia in pregnancy. Indian J Med Res. 2013;138:78-82.

A Singh, M Gupta, V Saini, S Jain. Ferric Carboxymaltose: a better option for treatment of postpartum iron deficiency anemia. Int J Basic Appl Med Sci. 2016;6(1):5-11.

Singh U, Singh N. Anemia in peuperium: Comparative study of efficacy and safety of Oral iron, Iron sucrose and Ferric carboxymaltose. Indian J Applied Res. 2016;5(6):741-2.

Singh S, Dhama V, Chaudhary R, Singh P. Comparing the safety and efficacy of intravenous iron sucrose and intravenous ferric carboxymaltose in treating postpartum anemia. Int J Reproduct Contraception Obstetr Gynecol. 2017;5(5):1451-6.

Funk F, Ryle P, Canclini C, Neiser S, Geisser P. The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose. Arzneimittelforschung. 2010;60(6a):345-53.

Naqash A, Ara R, Bader GN. Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials. BMC Womens Health. 2018;18(1):6

Wani S, Noushad M, Ashiq S. Regain study: Retrospective Study to Assess the Effectiveness, Tolerability, and Safety of Ferric Carboxymaltose in the Management of Iron Deficiency Anemia in Pregnant Women. Anemia. 2019;2019:4640635.

Patel A R, Patel V S, Patel P R. A comparative study of ferric carboxymaltose and iron sucrose as a parenteral iron treatment in iron deficiency anaemia during pregnancy. Int J Reprod Contracept Obstet Gynecol. 2020;9(6):2437-41.

Gupte SA, Venkataraman G, Shah AS, Mudholkar AS, Jangam SM. Clinical effects and safety of ferric carboxymaltose in pregnancy: An Indian real-life experience. J Obstetri Gynaecol Res. 2021;47(10):3464-70.

Bharat AM. Anemia management protocol for pregnant women. Available at: https://anemiamuktbharat. info/home/interventions. Accessed 04 January, 2021.

Breymann C, Milman N, Mezzacasa A, Bernard R, Dudenhausen J. Ferric carboxymaltose vs. oral iron in the treatment of pregnant women with iron deficiency anemia: an international, open-label, randomized controlled trial (FER-ASAP). J Perinat Med. 2017;45(4):443-53.